We are live on ! Find out more
BLUE

bluebird bio

Delisted

BLUE was delisted on the 30th of May, 2025.

177 hedge funds and large institutions have $1.9B invested in bluebird bio in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 68 increasing their positions, 61 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 61

11% more capital invested

Capital invested by funds: $1.71B → $1.9B (+$192M)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

10% less call options, than puts

Call options by funds: $22.4M | Put options by funds: $24.8M

5% less funds holding

Funds holding: 187177 (-10)

26% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 31

Holders
177
Holders Change
-10
Holders Change %
-5.35%
% of All Funds
4.72%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
23
Increased
68
Reduced
61
Closed
31
Calls
$22.4M
Puts
$24.8M
Net Calls
-$2.4M
Net Calls Change
+$11.8M
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
26
Baker Bros. Advisors
New York
$12.7M -$2.58M -4,555 -17%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$11.6M +$1.57M +2,777 +15%
Norges Bank
28
Norges Bank
Norway
$10.4M -$27.2K -48 -0.3%
Invesco
29
Invesco
Georgia
$9.88M -$191K -338 -2%
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
$9.75M +$416K +734 +4%
Millennium Management
31
Millennium Management
New York
$9.44M +$1.93M +3,408 +25%
CCI
32
Columbus Circle Investors
$8.71M -$6.11M -10,790 -41%
EA
33
Emerald Advisers
Pennsylvania
$8.4M -$2.92M -5,152 -26%
EAM
34
EverPoint Asset Management
Connecticut
$7.58M +$7.65M +13,510 New
GTC
35
Ghost Tree Capital
New York
$7.36M +$7.43M +13,124 New
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$7.27M -$1.25M -2,209 -15%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$7.24M +$571K +1,008 +8%
Axa
38
Axa
France
$7.08M +$643K +1,136 +10%
Mitsubishi UFJ Trust & Banking
39
Mitsubishi UFJ Trust & Banking
Japan
$6.91M -$188K -332 -3%
Goldman Sachs
40
Goldman Sachs
New York
$6.71M -$11M -19,398 -62%
EMFAT
41
Emerald Mutual Fund Advisers Trust
Pennsylvania
$6.65M -$2.56M -4,514 -28%
TCIM
42
TIAA CREF Investment Management
New York
$6.55M -$8.23M -14,530 -55%
BIM
43
BlackRock Investment Management
Delaware
$6.36M +$5.83M +10,294 +988%
UBS AM
44
UBS AM
Illinois
$6.32M -$510K -901 -7%
Charles Schwab
45
Charles Schwab
California
$6.3M +$1.93M +3,401 +43%
Bank of America
46
Bank of America
North Carolina
$5.63M -$1.21M -2,136 -18%
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$5.63M -$6.65M -11,734 -54%
CC
48
Casdin Capital
New York
$5.3M +$109K +193 +2%
GGHC
49
Gilder Gagnon Howe & Co
New York
$4.53M -$274K -484 -6%
AC
50
Armistice Capital
New York
$4.16M +$4.2M +7,411 New

BLUE Hedge Fund Activity: Q2 2016 in Review

177 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2016, worth a combined $1.9B — up 11% from $1.71B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of BLUE and 23 opened new positions — a net loss of 8 holders — while 61 trimmed existing stakes and 68 added.

The largest buyer was Wellington Management Group, adding an estimated $38.2M. The largest seller was Capital World Investors, cutting an estimated $17.6M.

  • 177 institutional investors held bluebird bio (BLUE) as of Q2 2016, down from 187 in Q1 2016.
  • Funds reported $1.9B of bluebird bio stock for Q2 2016, up 11% quarter-over-quarter.
  • 23 funds opened new bluebird bio positions in Q2 2016 and 31 closed out, a net change of -8 holders.
  • The largest bluebird bio buyer in Q2 2016 was Wellington Management Group, an estimated $38.2M added.
  • The largest bluebird bio seller in Q2 2016 was Capital World Investors, an estimated $17.6M sold.

Based on aggregated 13F filings for Q2 2016.